Firm

A year and a half ago, France made it compulsory to vaccinate farmed ducks against the avian influenza virus, in order to protect its meat and foie gras industries. To date, France is the only country to have taken this vaccination route. One of the two vaccines used, the self-amplifying messenger RNA (mRNA) vaccine, raises questions.

Since July 2023, the issue of patents on living organisms has been at the heart of debates in the European Union. These debates were sparked by the European Commission’s proposal to stop assessing the risks associated with GMOs, to stop labelling them as such, and to put an end to their detection and identification. In December 2024, a conference allowed several stakeholders of the debate to express their opinion.

The algae that live in rivers and the sea have been the focus of a great deal of attention in recent years. Whether micro, macro, green, brown, red… they are currently at the heart of an industrial development project for which the European Commission is active. These GMO algae could be deregulated if the European Commission’s July 2023 proposal were to be approved, as they will undergo genetic modification to be transformed into production facilities for pharmaceuticals, cosmetics, food and agrofuels. This article is a first dive into a world that has gone unnoticed until now.

At a time when the European Union is preparing new regulations on seeds, a look at the meetings between MEPs and the various stakeholders indirectly shows the weight of the multinationals in these procedures. This raises questions about the imbalance in the representation of these parties and the potential consequences for small seed companies, farmers and peasants.

After genetic sequences and DNA, here comes RNA, the new flagship molecule in biotechnology that is supposed to solve agricultural and health problems. Companies in this field are flourishing. Among them is GreenLight Biosciences, a company that was on the verge of bankruptcy when it was bought by the investment fund Fall Line Capital.

In January 2024, two Danish industrial giants of the microorganisms merged and Novonesis was born. This company sells “biosolutions” for all industrial and agricultural areas. “Bio” for biotechnological… and not biological, as it prefers to emphasize. This company uses microorganisms, often genetically modified, to make them produce enzymes.

Toulouse-based Micropep Technologies has just had one of its fungicidal micropeptides approved in the United States. The technology, developed and patented by this CNRS spin-off, is aiming for European approval by 2030. However, these micropeptides are raising questions about their potential impact on ecosystems.